• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Addition of immunosuppression does not improve outcome of supportive therapy for IgA nephropathy

byDavid ArsaniousandShaidah Deghan, MSc. MD
December 4, 2015
in Chronic Disease, Nephrology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

 

1. Addition of immunosuppression to supportive therapy did not lead to significantly improve outcomes described as full remission and a decrease in the eGFR of at least 15 ml/min/1.73 m2of BSA after 3 years of follow-up.

2. There was no significant difference between the rate of decreases in eGFR between patients who received supportive care alone and patients who received immunosuppression in addition to supportive care.

Evidence Rating Level: 2 (Good)         

Study Rundown: IgA nephropathy is the most common form of glomerulonephritis. The current Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend blockade of the renin-angiotensin system using an angiotensin-converting-enzyme inhibitor (ACEI) or an angiotensin II-receptor blocker (ARB) for patients with IgA nephropathy who have > 1 gram of urinary protein excretion per day. The KDIGO guidelines also recommend using systemic glucocorticoid immunosuppressive therapy in patients who have >1 gram of urinary protein excretion per day and a GFR > 50 mL per minute despite supportive treatment. To date, there have been conflicting controlled trials that have attempted to assess the utility of immunosuppressive glucocorticoid therapy in addition to standard supportive therapy (ACEI/ARB) over supportive therapy alone.

This study began with a six-month run-in phase, wherein all the patients received an ACEI/ARB. If after the six-month run-in phase, proteinuria remained elevated, patients entered the 3-year study phase. Patients either receive supportive care alone (supportive care group) or supportive care and immunosuppression (immunosuppression group). Patients whose proteinuria of eGFR did not respond sufficiently were found to be eligible for randomization in the 3-year study phase in either the supportive therapy group or immunosuppression group. The first primary endpoint of the study was full clinical remission at the end of the 3-year trial phase (as measured by protein to creatinine ratio <0.2), in which a statistically significant difference was found. The second primary endpoint of the study was a decrease in eGFR ≥ 15 mL/min/1.73m2, in which no significant difference was found.

RELATED REPORTS

Intravaginal conjugated oestrogen does not improve continuation rate of ring pessary use

Artificial intelligence based clinical decision systems are safe and effective for diabetes management

Epic Launchpad propels generative-AI into everyday hospital routines

This study draws strength from its randomized, controlled, two-group, parallel, group-sequential design. It also avoided the confounders that emerged in prior investigations of immunosuppression in IgA nephropathy through maintaining strict, consistent adherence to renin-angiotensin blockade. This study lacks in its ability to be extrapolated to cases of more advanced disease, such as patients with proteinuria >3.5 g per day or eGFR < 30 mL/min/1.73m2.

Click to read the study, published today in NEJM

Relevant Reading: IgA Nephropathy

In-Depth [randomized controlled trial]: In this study, 337 patients at 32 nephrology centers in Germany were enrolled in the initial 6-month run-in phase. During this phase, all the patients received comprehensive supportive therapy that included ACEI/ARB therapy to lower BP below 125/75 mmHg. If after the six-month run-in phase, proteinuria remained between 0.75 – 3.5 g per day, patients entered the 3-year study phase. These patients were randomized to receive either supportive care alone (supportive care group) or supportive care and immunosuppression (immunosuppression group). Patients with eGFR ≥ 60 mL/min/1.73m2 were randomly assigned to the immunosuppression group received glucocorticoid for 36 months while patients with eGFR 30 – 59 mL/min/1.73m2 were assigned to receive cyclophosphamide followed by azathioprine plus prednisolone for 36 months.

At the end of the run-in phase 177 patients were found to be eligible for randomization in the 3-year study phase. The primary endpoint showed a statistically significant higher percentage of full clinical remission at 36 months (5% of patients in the supportive-care group vs. 17% of patients in the immunosuppression group; p=0.01). In the analysis of available cases, it was found that 4/72 supportive care patients’ vs 17/71 immunosuppression patients exhibited full clinical remission (95% [CI], 1.55 – 18.66; p = 0.008).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Prevalence of neural tube defects unchanged over 20 years in Europe

Next Post

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors

RelatedReports

American Academy of Pediatrics recommends standards for adverse event disclosures
Chronic Disease

Intravaginal conjugated oestrogen does not improve continuation rate of ring pessary use

July 3, 2025
Pediatric DKA associated with recent acute care visits
Chronic Disease

Artificial intelligence based clinical decision systems are safe and effective for diabetes management

July 3, 2025
FDA-regulated clinical trials rarely report violations
AI Roundup

Epic Launchpad propels generative-AI into everyday hospital routines

July 3, 2025
#VisualAbstract: Routine Cerebral Embolic Protection Did Not Reduce Stroke Incidence during Transcatheter Aortic-Valve Implantation
All Specialties

#VisualAbstract: Routine Cerebral Embolic Protection Did Not Reduce Stroke Incidence during Transcatheter Aortic-Valve Implantation

July 3, 2025
Next Post
No benefit of erlotinib in combined hepatocellular carcinoma treatment

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors

Tramadol and Celecoxib effective pain control for hysteroscopy

Tramadol and Celecoxib effective pain control for hysteroscopy

Recurrence of endometrial hyperplasia following medical therapy is common

Recurrence of endometrial hyperplasia following medical therapy is common

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravaginal conjugated oestrogen does not improve continuation rate of ring pessary use
  • Artificial intelligence based clinical decision systems are safe and effective for diabetes management
  • Epic Launchpad propels generative-AI into everyday hospital routines
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.